News
LUCD
0.7965
-0.31%
-0.0025
Weekly Report: what happened at LUCD last week (0408-0412)?
Weekly Report · 6d ago
Lucid Diagnostics: Strong Buy Rating with Significant Market Potential Despite Near-Term Losses
TipRanks · 6d ago
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Blackstone, Coupang, Wells Fargo & Co and Union Pacific raise their targets. 4D Molecular Therapeutics and Astera Labs are among the companies with new coverage on Monday.
Reuters · 04/15 06:58
LUCID DIAGNOSTICS INC <LUCD.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $8 FROM $8.5
Reuters · 04/15 03:06
Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham
Dow Jones · 04/12 08:47
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Benzinga · 04/12 08:37
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
TipRanks · 04/11 20:45
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
TipRanks · 04/10 17:50
Weekly Report: what happened at LUCD last week (0401-0405)?
Weekly Report · 04/08 12:11
Weekly Report: what happened at LUCD last week (0325-0329)?
Weekly Report · 04/01 12:07
Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position
TipRanks · 03/28 11:07
Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives
TipRanks · 03/27 18:45
Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 03/27 14:13
Lucid Diagnostics Price Target Cut to $3.00/Share From $3.80 by Cantor Fitzgerald
Dow Jones · 03/27 14:13
Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3
Benzinga · 03/27 14:05
Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham
Dow Jones · 03/27 09:30
Buy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare Reimbursement
TipRanks · 03/27 09:25
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Benzinga · 03/27 09:20
*PAVmed 4Q Adj Loss/Shr $1.33 >PAVM
Dow Jones · 03/26 23:34
*PAVmed 4Q Rev $1M >PAVM
Dow Jones · 03/26 23:33
More
Webull provides a variety of real-time LUCD stock news. You can receive the latest news about Lucid Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.